New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
16:05 EDTCYCCCyclacel Pharmaceuticals reports Q4 EPS (19c), consensus (33c)
Reports Q4 revenue $299,000, consensus $90,000. Company reports cash position at year end was $31.1M compared to $16.4M at the end of 2012.
News For CYCC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 12, 2015
16:12 EDTCYCCCyclacel Pharmaceuticals reports Q1 EPS (19c), one estimate (25c)
Reports Q1 revenue $512,000 vs. $396,000 last year. "Approximately 20% of the prespecified events remain to be observed before we unblind SEAMLESS, our pivotal, Phase 3 study of sapacitabine in patients aged 70 years or older with acute myeloid leukemia (AML) who are unfit or have refused intensive chemotherapy. We expect this to occur between the second half of 2015 and the first half of 2016. As we continue study follow-up, we have begun preparations for submission of a Pediatric Investigation Plan to the European Medicines Agency. In parallel with sapacitabine activities, we are progressing development of CYC065, our novel, second-generation cyclin dependent kinase 2/9 inhibitor. Following submission of our Investigational New Drug application, we have received clearance from the FDA to begin a first-in-human, Phase 1 clinical trial of CYC065, which will commence following institutional review board approval. We have cash resources for the next two years which are sufficient to advance these programs and deliver on our key milestones," said CEO Spiro Rombotis.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use